[18F]FES PET/CT Imaging for Uterine Cancer
Trial Summary
Will I have to stop taking my current medications?
If you are currently taking tamoxifen or fulvestrant, you will need to stop and wait for 8 weeks or 28 weeks, respectively, before the scan. For other medications, the protocol does not specify any requirements.
What data supports the effectiveness of the drug 18F-Fluoroestradiol for uterine cancer?
Research shows that 18F-FES PET/CT imaging can help in diagnosing and understanding the behavior of uterine tumors by measuring estrogen receptor activity, which is important since some uterine cancers are estrogen-dependent. This imaging technique has been effective in breast cancer for similar reasons, suggesting potential usefulness in uterine cancer as well.12345
Is [18F]FES PET/CT imaging safe for humans?
How does [18F]FES PET/CT imaging differ from other treatments for uterine cancer?
[18F]FES PET/CT imaging is unique because it uses a special tracer to visualize estrogen receptors in the body, helping to assess the presence and behavior of uterine tumors. This method is different from traditional imaging as it provides detailed information about the tumor's estrogen receptor status, which can be crucial for diagnosis and treatment planning.345910
What is the purpose of this trial?
Women with known or suspected recurrent or metastatic uterine cancer may be eligible for this study. Patients may participate in this study if they are at least 18 years of age, most participants will be receiving care at the clinical practices of the University of Pennsylvania.\[18F\]fluoroestradiol (FES) PET/CT imaging will be used to evaluate estrogen receptor (ER) activity in areas of disease known by standard of care imaging (e.g. CT, MRI, Bone Scan, FDG PET/CT, ultrasound) or clinical exam. For patients starting a new line of therapy, imaging will occur prior to starting new therapy. For patients who completed an initial scan and are starting new therapy, some patients may also undergo a second FES PET/CT scan at the time of suspected progression of disease to compare for changes in FES uptake measures (prior to initiation of next line therapy). The selection of therapy will be made by a treating physician and will not be affected by participation in this imaging study. Results of the FES PET/CT scan may be shared with the treating physician or subject by request but will not be used to make clinical decisions about treatment.
Research Team
Neil Taunk, MD
Principal Investigator
Abramson CC
Eligibility Criteria
This trial is for women aged 18 or older with recurrent, metastatic, or untreated uterine cancer confirmed by biopsy or imaging. Participants must have at least one lesion outside the liver and cannot be pregnant. Those on tamoxifen or fulvestrant need a washout period before scanning. The study requires informed consent.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Initial Imaging
Participants undergo the first FES PET/CT scan to evaluate estrogen receptor activity
Optional Second Imaging
Participants may undergo a second FES PET/CT scan at the time of disease progression to compare changes in FES uptake
Follow-up
Participants are monitored for changes in FES uptake and progression-free survival
Treatment Details
Interventions
- 18F-Fluoroestradiol
Find a Clinic Near You
Who Is Running the Clinical Trial?
Abramson Cancer Center at Penn Medicine
Lead Sponsor